Intuniv (guanfacine)
- Region
- 🇪🇺 EU
- Active substance
- guanfacine
- Company
- Takeda Pharmaceuticals International AG Ireland
- Status
- Authorised
- Therapeutic area
- Attention Deficit Disorder with Hyperactivity
- EU approval
- Thu 17 Sep 2015
- Application
- EMEA/H/C/003759
- ATC
- C02AC02
- Official record
- www.ema.europa.eu
Indication
Intuniv is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. Intuniv must be used as a part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Paxneury Authorised · Neuraxpharm Pharmaceuticals S.L.
Follow Intuniv
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.